LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Potential Biomarker Found for Severe Viral Hemorrhagic Fevers

By LabMedica International staff writers
Posted on 20 Jul 2016
Print article
Image: A scanning electron micrograph (SEM) of Puumala virus, a species of hantavirus (Photo courtesy of Hans R. Gelderblom, Freya Kaulbars/RKI).
Image: A scanning electron micrograph (SEM) of Puumala virus, a species of hantavirus (Photo courtesy of Hans R. Gelderblom, Freya Kaulbars/RKI).
Hemorrhagic fever with renal syndrome (HFRS) and Crimean-Congo hemorrhagic fever (CCHF) are common representatives of viral hemorrhagic fevers still often neglected in some parts of the world.

Infection with Dobrava or Puumala virus (HFRS) and Crimean-Congo hemorrhagic fever virus (CCHFV) can result in a mild, nonspecific febrile illness or as a severe disease with hemorrhaging and high fatality rate. An important factor in optimizing survival rate in patients with VHF is instant recognition of the severe form of the disease for which significant biomarkers need to be elucidated.

Medical faculty members of the University of Ljubljana (Ljubljana, Slovenia) examined 128 serum samples of patients with hemorrhagic fever, HFRS patients were hospitalized in different Slovenian hospitals and clinical diagnosis was confirmed with serological or molecular tests. From 72 HFRS patients included in the study, 24 were infected with Dobrava virus (DOBV) and 48 were infected with Puumala virus (PUUV). Additionally, they analyzed 29 serial samples from seven HFRS patients. Fifty-six patients from Kosovo with confirmed CCHF were also included in the study.

The scientists we investigated the role of High Mobility Group Box 1 (HMGB1) or amphoterin as a prognostic marker for the severe form of HFRS and CCHF. The concentration of HMGB1 was measured with commercially available HMGB1 capture enzyme-linked immunosorbent assay (ELISA) kit (Chondrex, Redmond, WA, USA) and samples were measured in duplicate. For each patient a detailed medical chart was collected and significant laboratory parameters were analyzed. Additionally, serum samples of 61 healthy donors were tested and processed as patients’ samples.

The investigators found that HMGB1 levels were increased in patients with CCHFV, DOBV or PUUV infection. More importantly, concentration of HMGB1were higher in patients with severe disease progression when compared to the mild clinical course of the disease. The results indicate that HMGB1 could be a useful prognostic biomarker for disease severity in PUUV and CCHFV infection, where the difference between the mild and severe patients group was highly significant and even in patients with severe DOBV infection concentrations of HMGB1 were 2.8–times higher than in the mild group. The study was published on June 27, 2016, in the journal Public Library of Science Neglected tropical Diseases.

Related Links:
University of Ljubljana
Chondrex

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more